CHEMOCENTRYX
ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.
CHEMOCENTRYX
Industry:
Biotechnology Health Care Medical Device
Founded:
1997-01-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.chemocentryx.com
Total Employee:
101+
Status:
Active
Contact:
+1.650.210.2900
Email Addresses:
[email protected]
Total Funding:
634.34 M USD
Technology used in webpage:
SPF SSL By Default Mobile Non Scaleable Content Amazon IPv6 Google Maps ReCAPTCHA Microsoft Azure DNS Google Maps API Apple Mobile Web App Capable
Similar Organizations
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Intarcia Therapeutics
Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Myomo
Myomo develops devices with myoelectric prosthetic technology to restore the mobility of individuals with muscle weakness.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Hercules Capital
Hercules Capital investment in Post-IPO Debt - ChemoCentryx
Alta Partners
Alta Partners investment in Series E - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series E - ChemoCentryx
HealthCap
HealthCap investment in Series E - ChemoCentryx
Glaxo Group
Glaxo Group investment in Series D - ChemoCentryx
OrbiMed
OrbiMed investment in Series D - ChemoCentryx
Gimv
Gimv investment in Series D - ChemoCentryx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - ChemoCentryx
Alta Partners
Alta Partners investment in Series D - ChemoCentryx
Key Employee Changes
| Date | New article |
|---|---|
| 2021-10-11 | ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer |
Official Site Inspections
http://www.chemocentryx.com Semrush global rank: 4.64 M Semrush visits lastest month: 2.14 K
- Host name: cloudproxy10158.sucuri.net
- IP address: 192.124.249.158
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
